Ken Song

Company: Candid Therapeutics

Job title: President & Chief Executive Officer

Seminars:

Panel Discussion: TCEs vs Cell Therapy: Comparing the Pros & Cons to Build Smarter Pipelines with the Right Modality for the Right Target 11:00 am

As T-cell engagers (TCEs) rapidly emerge from oncology into the autoimmune space, the field is facing a crucial inflection point: how do TCEs stack up against T-cell therapies in terms of specificity, efficacy, and durability? This panel brings together leading voices spanning TCE and cell therapy modalities to debate how these technologies co-exist, compete, or…Read more

day: Day One

Engineering Deep & Durable B Cell Depletion in Autoimmune Disease: Translating T-Cell Engager Candidates Beyond Oncology 2:00 pm

Introducing cizutamig and CND261, a BCMAxCD3 and CD20xCD3 bispecific T-Cell engager, respectively. Both were originally developed in oncology and are now advancing into autoimmune disease Discussing what is known and unknown on targeting different B cell antigens (e.g. BCMA, CD19, CD20) to maximize clinical benefit in autoimmune diseases Sharing views on different product profiles with…Read more

day: Day One